Author

Carrie L. Melvin

Observed names: C. L. Melvin, C. Melvin, C.L. Melvin, Carrie Melvin

Institutions: EMD Serono, Inc. (United States), Kura Oncology (United States)

Observed institutions: Fox Chase Cancer Center, Roswell Park Comprehensive Cancer Center, Mayo Clinic, Pfizer (United States), University of South Florida, Moffitt Cancer Center, Hospital Universitario 12 De Octubre, EMD Serono, Inc. (United States), Dana-Farber Cancer Institute, Kura Oncology (United States), McGill University

OpenAlex ID: A5085649465

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

2007 · Johann S. de Bono, Gerhardt Attard, et al. · Clinical Cancer Research · 192

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

2008 · Martha Q. Lacy, Melissa Alsina, et al. · Journal of Clinical Oncology · 163

Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)

2007 · D. D. Karp, L. G. Paz-Ares, et al. · Journal of Clinical Oncology · 36

Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors

2007 · Michaël Pollak, Peter D. Eisenberg, et al. · Cancer Research · 9

An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck.

2017 · Alan Loh Ho, Nicole Grace Chau, et al. · Journal of Clinical Oncology · 6

Phase 1 first-in-human dose escalation study of cp-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor

2006 · M. Lacy, M. Alsina, et al. · Journal of Clinical Oncology · 6

Inhibition of the insulin like growth factor 1 receptor by a specific monoclonal antibody in multiple myeloma

2005 · A. Gualberto, M. Alsina, et al. · Journal of Clinical Oncology · 6

Preliminary Results From an Open‐label, Phase Ii Study of Tipifarnib in Relapsed or Refractory Peripheral T‐cell Lymphoma

2017 · T. Witzig, L. Sokol, et al. · Hematological Oncology · 5

Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.

2007 · Martha Q. Lacy, Melissa Alsina, et al. · Blood · 5

6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

2007 · L. Paz-Ares, M.N. Pollak, et al. · European Journal of Cancer Supplements · 1

PD3-3-1: A phase Ib/randomized phase II, non-comparative, open label trial of paclitaxel and carboplatin with or without the anti-IGF-IR antibody CP-751,871 as first-line treatment for advanced non-small cell lung cancer (NSCLC)

2007 · Daniel D. Karp, L.G. Paz-Ares, et al. · Journal of Thoracic Oncology

Works count: 11

Citation count: 429

H-index: 6

I10-index: 3